List of Excipients in Branded Drug VIBERZI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	VIBERZI	eluxadoline	61874-075	CELLULOSE, MICROCRYSTALLINE	2033-03-14
Allergan Inc	VIBERZI	eluxadoline	61874-075	CROSPOVIDONE	2033-03-14
Allergan Inc	VIBERZI	eluxadoline	61874-075	FERRIC OXIDE RED	2033-03-14
Allergan Inc	VIBERZI	eluxadoline	61874-075	FERRIC OXIDE YELLOW	2033-03-14

Viberzi Excipient Strategy and Commercial Opportunities for Eluxadoline

Last updated: September 29, 2026

Viberzi contains eluxadoline, an orally administered, immediate-release tablet approved for adults with irritable bowel syndrome with diarrhea, or IBS-D. The commercial opportunity is concentrated in generic or alternative oral solid-dose development, excipient substitution, supply-chain optimization, and differentiated products that improve tolerability or manufacturing economics. The principal constraints are Viberzi’s safety labeling, controlled-substance status, relatively narrow indication, and the need to demonstrate pharmaceutical equivalence without altering eluxadoline exposure.

What is Viberzi and how is it formulated?

Viberzi is supplied as 75 mg and 100 mg film-coated tablets for twice-daily oral administration with food. The active ingredient is eluxadoline, a mixed opioid receptor agonist and antagonist used to treat IBS-D in adults. The FDA-approved product is an immediate-release tablet rather than an extended-release or modified-release system.[1]

The labeled inactive ingredients are:

Formulation component	Reported function
Microcrystalline cellulose	Diluent and compression aid
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and moisture-control aid
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-forming coating polymer
Sodium lauryl sulfate	Wetting or surfactant component
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier and colorant

The formulation is technically conventional. Its commercial value lies in achieving rapid tablet disintegration, consistent dissolution, acceptable mechanical strength, and scalable film coating while controlling excipient variability.

What excipients are used in Viberzi tablets?

The core formulation uses microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and magnesium stearate. The coating uses polyvinyl alcohol, sodium lauryl sulfate, talc, and titanium dioxide.[1]

The label does not identify the quantitative percentage of each excipient. Competitors therefore must develop their own quantitative formula and demonstrate that the finished product meets applicable pharmaceutical-equivalence and quality standards.

What excipient strategy is most attractive for a Viberzi generic?

The highest-value strategy is a conventional immediate-release tablet with a low-risk excipient profile and a robust manufacturing process. A generic developer does not need to replicate every inactive ingredient, but changes must not affect identity, strength, quality, purity, potency, stability, or performance.

Immediate-release tablet strategy

The core development priorities are:

1. Rapid and reproducible disintegration.
2. Dissolution comparable to the reference product.
3. Low tablet friability and adequate hardness.
4. Uniformity of dosage units at both 75 mg and 100 mg strengths.
5. Stable film coating with minimal moisture uptake.
6. Efficient scale-up for high-speed compression and coating.

Crospovidone is commercially attractive because it provides rapid disintegration without requiring a large tablet mass. Microcrystalline cellulose supports direct compression and improves tablet compactability. Colloidal silicon dioxide can improve powder flow, but excessive use may reduce tablet strength or complicate blend uniformity. Magnesium stearate requires controlled blending because over-lubrication can slow dissolution.

Excipient substitution opportunities

Potential substitutions include:

Reference excipient	Potential alternative	Commercial rationale
Crospovidone	Croscarmellose sodium or sodium starch glycolate	Supply diversification and formulation-cost control
Microcrystalline cellulose	Spray-dried lactose, mannitol, or silicified microcrystalline cellulose	Improved flow, compactability, or patient acceptability
Colloidal silicon dioxide	Alternative pharmaceutical glidants	Supplier diversification
Magnesium stearate	Sodium stearyl fumarate or other approved lubricants	Reduced hydrophobicity or improved dissolution
Polyvinyl alcohol coating	Hypromellose-based coating	Broader coating-supplier availability
Titanium dioxide	Alternative approved color or opacifier system	Regulatory and market-specific coating requirements

Any substitution must be supported by comparative dissolution, stability, impurity, process-validation, and bioequivalence data where required. A formulation that appears simpler may create greater regulatory risk if it changes eluxadoline release or absorption.

What formulation patents protect Viberzi?

The commercial product is protected through a combination of active-ingredient, formulation, method-of-use, and regulatory exclusivity rights. The FDA Orange Book is the controlling source for patents listed against the Viberzi NDA and should be reviewed before filing an abbreviated new drug application, or ANDA.[3]

The relevant diligence categories are:

Protection category	Potential relevance to a competitor
Eluxadoline compound patents	May cover the active molecule and related chemical forms
Composition-of-matter rights	Usually the strongest early protection
Formulation patents	May cover tablet composition, excipient ranges, or release characteristics
Method-of-use patents	May cover treatment of IBS-D or defined patient populations
Manufacturing patents	May cover salt formation, crystallization, purification, or solid-state control
Regulatory exclusivity	May delay ANDA approval even after some patent claims expire

A generic developer should distinguish between patents listed in the Orange Book and patents that are enforceable against a particular product configuration. A formulation change can avoid some composition claims but will not necessarily avoid method-of-use or active-ingredient claims.

When did Viberzi lose FDA exclusivity?

Viberzi received FDA approval on May 27, 2015. As a new chemical entity, it received five years of NCE exclusivity, subject to the applicable statutory framework. That period would have ended in May 2020, although patent rights and any other regulatory exclusivity could extend later entry.[1][3]

The relevant entry date for a generic remains dependent on the Orange Book patent listing, litigation outcomes, settlement terms, and any applicable pediatric or patent-term extensions.

What is the Orange Book status of Viberzi?

The Orange Book identifies approved drug products, therapeutic-equivalence evaluations, listed patents, and applicable exclusivity information.[3] Viberzi’s Orange Book review should cover:

• NDA 207968.
• Both the 75 mg and 100 mg strengths.
• Listed patent numbers and expiration dates.
• Any use codes associated with method-of-use patents.
• The status of any approved ANDAs.
• Whether a patent challenge has triggered a 30-month stay.
• Whether the product remains listed as a reference product for ANDA purposes.

Because Orange Book entries can change through patent-listing updates, delistings, litigation, or regulatory action, a current submission strategy should rely on the FDA’s live database rather than an archived patent summary.

Which companies are challenging Viberzi, and what is the Paragraph IV risk?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The commercial impact depends on whether the first filer qualifies for 180-day generic exclusivity and whether the patent owner files an infringement action within the statutory period.

For Viberzi, the principal generic risks are:

Risk	Impact
Active-ingredient patent challenge	Could determine whether any generic can enter before the full patent term
Method-of-use challenge	May require labeling restrictions or a skinny-label strategy
Formulation patent challenge	Could force a non-infringing excipient architecture
Manufacturing patent challenge	May require an alternative synthesis or crystallization process
Controlled-substance compliance	Adds DEA registration, recordkeeping, and distribution obligations
Limited market size	Can reduce the number of economically viable challengers

The most attractive ANDA strategy would use an immediate-release tablet with a non-infringing excipient composition and a label limited to non-protected uses, if method-of-use patents remain relevant. The commercial value of a first Paragraph IV launch would depend on remaining patent duration, litigation costs, and the size of the IBS-D market at entry.

What regulatory requirements apply to a Viberzi generic?

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The product must match the reference in active ingredient, dosage form, strength, route of administration, and applicable quality attributes.

The key regulatory workstreams are:

Bioequivalence

The applicant must establish comparable systemic exposure. Because eluxadoline is administered with food, food-effect considerations are important. The reference labeling specifies administration with food, and the generic development program must account for that instruction.[1]

Dissolution and product performance

The applicant should develop discriminatory dissolution methods that detect changes in:

• Disintegration time.
• Tablet hardness.
• Lubrication level.
• Coating weight.
• Excipient grade.
• Manufacturing scale.
• Storage humidity.

A formulation that passes a single dissolution condition but fails under discriminatory conditions creates post-approval change risk.

Stability

The tablet requires stability assessment under ICH conditions, including evaluation of:

• Assay and degradation products.
• Dissolution.
• Water content.
• Tablet hardness and friability.
• Coating integrity.
• Microbial quality where relevant.

Excipient moisture and lubricant variability are likely to be more important than novel delivery technology.

What manufacturing and IP barriers affect Viberzi competitors?

The principal barrier is not complex delivery technology. It is the combined requirement to manufacture a low-dose active ingredient consistently, control blend uniformity, and maintain dissolution performance across commercial scale.

Eluxadoline has a low drug load relative to the total tablet mass. That increases the importance of:

• Particle-size distribution.
• Powder segregation control.
• Pre-blending.
• Content-uniformity sampling.
• Granulation or direct-compression selection.
• API particle engineering.
• Lubrication-time control.

A direct-compression process may reduce capital requirements, but it can be sensitive to powder flow and segregation. Dry or wet granulation can improve uniformity and manufacturability, but introduces additional process steps and potential degradation or dissolution changes.

Manufacturing patents may also create barriers if they cover a specific solid form, purification route, or process parameter. A process that uses a different solvent system or crystallization sequence may reduce infringement risk but require additional impurity and solid-state characterization.

What commercial opportunities exist for Viberzi excipient suppliers?

The addressable opportunity extends beyond a single generic tablet.

Excipient supply

The most immediate opportunity is supply of high-performance grades of:

• Microcrystalline cellulose.
• Crospovidone.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Film-coating premixes.
• Alternative lubricants.
• Low-moisture excipients.

Suppliers can compete on batch-to-batch consistency, regulatory documentation, global availability, and technical support rather than only unit price.

Formulation development services

Contract development organizations can offer:

• Reference-product characterization.
• Excipient compatibility studies.
• Direct-compression screening.
• Comparative dissolution modeling.
• Bioequivalence-risk reduction.
• Scale-up and process validation.
• ANDA CMC support.

Differentiated oral products

A 505(b)(2) strategy could explore alternative dosage forms or administration systems, but the commercial case is narrower. Potential concepts include:

• Smaller tablets.
• Improved swallowability.
• Orally disintegrating tablets.
• Sprinkle or multiparticulate formulations.
• Packaging designed for controlled-substance compliance.
• Products aimed at patients with swallowing difficulties.

These approaches would face additional clinical, CMC, and regulatory requirements. They would also need a clear commercial advantage over a low-cost generic tablet.

How strong is the Viberzi patent estate?

The estate is commercially meaningful because protection can extend beyond the basic drug approval through composition, use, formulation, and manufacturing claims. Its practical strength depends on the remaining enforceable claims, Orange Book listing status, claim scope, and the availability of non-infringing formulations.

The estate is weaker where:

• The core active-ingredient claims have expired.
• Method-of-use claims can be avoided through label design.
• The reference formulation uses conventional excipients.
• A competitor can develop a bioequivalent formulation with different excipient grades.
• No clinically meaningful delivery technology differentiates the product.

The estate is stronger where:

• Solid-state or process claims are difficult to design around.
• Formulation claims cover broad excipient ranges.
• Use codes cover the primary commercial indication.
• Regulatory exclusivity or litigation delays generic approval.
• API supply is concentrated among a small number of qualified manufacturers.

How does Viberzi compare with other IBS-D treatments?

Viberzi competes with non-opioid and symptomatic IBS-D treatments, including rifaximin, loperamide, bile-acid sequestrants, dietary interventions, and off-label therapies. Its differentiation is the combination of opioid-receptor activity and an IBS-D-specific FDA indication.

Product or therapy	Primary commercial distinction	Excipient opportunity
Viberzi, eluxadoline	Prescription oral tablet for IBS-D	Generic tablet and alternative oral solid dose
Xifaxan, rifaximin	Non-systemic antibiotic approach	Tablet and rifaximin formulation competition
Imodium, loperamide	Broad over-the-counter antidiarrheal use	ODT, chewable, liquid, and combination products
Bile-acid sequestrants	Often used when bile-acid malabsorption is suspected	Powder, tablet, and improved-palability formats
Dietary therapies	Non-drug management	Limited pharmaceutical excipient opportunity

Viberzi’s commercial opportunity is therefore dependent on prescription persistence, physician preference, payer coverage, and generic price erosion rather than on a large untreated population alone.

What revenue exposure and launch scenarios exist?

A Viberzi generic would likely face three launch scenarios:

Scenario	Market outcome
Early or at-risk launch	Higher price opportunity but substantial patent and damages exposure
First approved generic after patent resolution	Potential 180-day exclusivity advantage, followed by rapid competition
Later multi-source entry	Lower margins, with value shifting to manufacturing efficiency and supply reliability

Revenue exposure is affected by:

• The number of approved generic suppliers.
• Payer substitution.
• Branded-product persistence.
• Patient switching rates.
• Wholesale acquisition price.
• Controlled-substance distribution requirements.
• The proportion of prescriptions covered by government programs.

An excipient supplier with a qualified, globally available platform may capture value from multiple ANDA applicants even if no single generic sponsor achieves market leadership.

What licensing and partnering opportunities exist?

Licensing opportunities are most credible in four areas:

1. Regional rights for eluxadoline tablets.
2. ANDA-ready formulations with established bioequivalence data.
3. Non-infringing manufacturing processes.
4. Excipient platforms that improve compression, dissolution, or stability.

A formulation license is more valuable when it includes process parameters, analytical methods, scale-up data, and regulatory-support documentation. A simple qualitative excipient list has limited licensing value because the listed ingredients are conventional and readily available.

No major licensing structure should be assumed without a transaction-specific review of the current holder, regional rights, manufacturing agreements, and patent assignments.

Key Takeaways

• Viberzi is an immediate-release eluxadoline tablet available in 75 mg and 100 mg strengths.
• Its formulation uses conventional excipients, creating practical opportunities for substitution and cost reduction.
• The strongest generic strategy is a robust immediate-release tablet with controlled disintegration, dissolution, blend uniformity, and film coating.
• Excipient suppliers can compete through consistency, global supply, low-moisture grades, and formulation support.
• The main regulatory pathway is an ANDA, with food-effect and bioequivalence requirements tied to the reference product.
• Patent diligence must cover active-ingredient, formulation, method-of-use, manufacturing, and Orange Book-listed rights.
• Commercial upside is greatest for an early approved generic or a differentiated oral product with a clear patient or manufacturing advantage.
• Controlled-substance obligations and Viberzi’s safety labeling increase operational and commercial risk.
• Conventional excipients limit the value of a basic formulation license; process knowledge and regulatory-ready documentation create greater value.

FAQs

Can a Viberzi generic use different excipients?

Yes. An ANDA does not generally require an identical inactive-ingredient formula, but the alternative formulation must meet applicable pharmaceutical-equivalence, quality, stability, dissolution, and bioequivalence requirements.

Is an extended-release version of eluxadoline commercially attractive?

Potentially, but it would likely require a 505(b)(2) pathway or another regulatory route rather than a straightforward ANDA. The product would need a clinically defensible benefit over the immediate-release reference tablet.

Do Viberzi excipients create major patient-safety restrictions?

The principal safety restrictions arise from eluxadoline, not the conventional tablet excipients. The FDA label includes important contraindications and warnings involving pancreatitis, sphincter of Oddi dysfunction, gallbladder status, constipation, alcohol use, and hepatic impairment.[1][2]

Can an excipient supplier obtain exclusivity for a Viberzi formulation?

Exclusivity would generally require patentable technical subject matter, such as a non-obvious composition, manufacturing process, solid form, stability improvement, or clinically meaningful delivery system. A conventional substitution alone may not support strong exclusivity.

Is Viberzi suitable for a biosimilar development strategy?

No. Eluxadoline is a small-molecule drug, not a biologic. Competitive development would use an ANDA, 505(b)(2) application, or a full NDA pathway rather than a biosimilar application.

References

1. U.S. Food and Drug Administration. (2015). Viberzi (eluxadoline) prescribing information.
2. U.S. Food and Drug Administration. (2017). FDA warns about increased risk of serious pancreatitis with Viberzi in patients without a gallbladder.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
5. U.S. Food and Drug Administration. (2015). Inactive ingredient database.